BC
VBIV

Burleson & Co’s VBI Vaccines, Inc. New Common Stock (Canada) VBIV Stock Holding History

Burleson & Co’s Portfolio VBIV Stock Details VBIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-22
Closed -$2K – 411
2021
Q2 		$2K Hold
22
– – ﹤0.01% 321
2021
Q1 		$2K Buy
+22
New +$2.23K ﹤0.01% 320

Other funds holding VBIV

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
GAI
General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Burleson & Co's VBIV Position: Q3 2021 in Review

Burleson & Co sold out of VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) in Q3 2021, closing a stake of 22 shares — an estimated $2K sold.

Burleson & Co first reported a position in VBIV in Q1 2021 and held it in 2 quarters. The position peaked at $2K in Q2 2021. 126 funds tracked by Wall St. Rank hold VBIV as of Q3 2021.

  • Burleson & Co reported no remaining VBI Vaccines, Inc. New Common Stock (Canada) position as of Q3 2021 after selling out during the quarter.
  • Burleson & Co sold 22 VBI Vaccines, Inc. New Common Stock (Canada) shares in Q3 2021, an estimated $2K.
  • Burleson & Co first reported a position in VBI Vaccines, Inc. New Common Stock (Canada) in Q1 2021 and held it in 2 quarters.
  • Burleson & Co's VBI Vaccines, Inc. New Common Stock (Canada) position peaked at $2K in Q2 2021.
  • 126 funds tracked by Wall St. Rank held VBI Vaccines, Inc. New Common Stock (Canada) as of Q3 2021.

Based on Burleson & Co's 13F filing for Q3 2021, filed 2 Nov 2021.